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Background: Hereditary hemochromatosis is a disease associated with iron deposition which is caused by
the mutations in ‘‘hereditary Fe (iron)” (HFE) gene.
Case: The 16-year-old male patient was diagnosed with hereditary hemochromatosis after
c.100747G>A heterozygous c.340+4 T>C heterozygous mutations were detected in HFE gene analysis
after a suspicion of hemochromatosis due to increase of hemoglobin value from 14.8 g/dL to 16.8 g/dL
and the level of ferritin from 68 ng/ml to 300 ng/ml in routine check-up controls in two-years period.
In addition, due to low mean corpuscular volume (MCV) (76 fL), and mean corpuscular hemoglobin
(MCH) (26 pg) levels, gene mutation analysis was carried out and the patient was also shown to carry
a thalassemia 3.7 deletions.
Conclusion: Early diagnosis of hemochromatosis is important in terms of prognosis and morbidity. We
aimed to emphasize that we can easily diagnose the disease by performing genetic analysis in cases with
suspected hemochromatosis even they have no complaints.
 2018 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hemochromatosis is the abnormal accumulation of iron in
parenchymal organs, leading to organ toxicity. It is the most com-
mon autosomal recessive genetic disorder and the most common
cause of severe iron overload [1]. Hemochromatosis is classified
as primary and secondary. In some diseases with deposition of
iron, there is no secondary disorder that causes the disease and
they are classified as primary hemochromatosis. Secondary
hemochromatosis develops secondary to another disease such as
thalassemia with ineffective erythropoiesis [2].
Hereditary hemochromatosis (HH) is a disorder of iron metabo-
lism with genetic and environmental factors involved in pathogen-
esis and causes progressive iron accumulation in various
parenchymal organs. In 1996, Feder et al. identified hereditary Fe
(iron) gene mutations (HFE) responsible for HH. With the detection
of these mutations, a great deal of improvement has been made in
the identification of the disease [1]. The most common type of HH
seen due to changes in the HFE gene is called HFE-associated HH.Along with the identification of new mutations, other subgroups
of the disease have also been identified and they are referred to
as non-HFE related HH (non-HFE).
The HFE gene encodes a 343-amino acid HFE protein which is
a major histocompatibility complex (MHC) class 1 molecule and
found in the HLA-A locus on chromosome 6. HFE protein is a
transmembrane protein with intracellular and extracellular com-
ponents and plays an important role in the regulation of iron
metabolism [3]. Two important mutations in the HFE gene have
been identified. C282Y mutation takes place with tyrosine substi-
tution instead of the cysteine in the codon 282 whereas H63D
mutation is formed by aspartate passage instead of histidine in
the codon 63. The biological effect of the first mutation is stron-
ger than the H63D mutation. In their study, Feder et al. found
that 83% of the HH cases were homozygous (C282Y) and 8% were
heterozygous (C282Y/H63D). Conformational structure of the pro-
tein is impaired and the iron absorption increases after HFE gen
mutation. HH type 1 Classical hereditary hemochromatosis is
characterized by HFE gene mutation [4]. Juvenile hemochromato-
sis, defined as type 2; type 2A if a hemojuvelin (HJV) mutation is
present, or type 2B if a hepsin (HAMP) mutation is present [5].
Type 3 hemochromatosis occurs as a result of transferrin receptor
2 (TfR-2) mutation. Type 4 haemochromatosis occurs due to
ferroporphyrin mutation [6].
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in hereditary hemochromatosis is the measurement of ferritin
and transferrin saturation values. The analysis of genetic mutations
in susceptible cases is important in diagnosis [7]. Direct genetic
screening should be performed in the first degree relatives of indi-
viduals who are defined with hereditary hemochromatosis [8].2. Case report
A 14-year-old male patient was admitted to the Pediatrics Clinic
for routine check-up. His physical examination was normal and
blood analysis revealed: erythrocyte (RBC) count 6.07  106/uL
(4.1–5.1  106/uL), hemoglobin (Hb) 14.6 g/dL (13–16 g/dL), hema-
tocrit (Hct)%43.1 (%37–49), mean corpuscular volume (MCV) 71 fL
(73–95 fL), mean corpuscular hemoglobin (MCH) 24.1 pg
(26–30 pg), ferritin 68 ng/ml (13–68 ng/ml). On peripheral blood
smear, mild hypochromia and anisocytosis observed. His family
history was clear. There was no significant finding in his or family’s
history.
After 2 years, at the age of 16, he was admitted to the Pediatrics
clinic for a routine check up once more. His physical examination
was normal. However, it was found that RBC count was
6.07  106/uL, Hb was14.6 g/dL, Hct was 43.1%, MCV and MCH
were 71 fL and 24.1 pg, respectively, ferritin level was 300 ng/ml.
The patient had no changes in his nutrition status or was not on
medication in that period. Serum iron, iron binding capacity, and
other acute phase reactants were normal. Due to low levels of
MCV and MCH, he was suspected as having thalassemia triat, how-
ever, no abnormal hemoglobin was detected in his hemoglobin
electrophoresis (Hb A2%2.1). He was diagnosed as alpha tha-
lassemia due to detected a3.7, a4.2 single gene deletion in
‘‘Multiplex Ligation-Dependent Probe Amplification” (MLPA)
method (Fig. 1). Erythropoietin levels analysed for polycythaemia
were normal (7 IU/L) and a clinically insignificant wild type (nor-
mal) genomic sequence involving JAK2-V617F mutation was
detected in DNA point mutation mini sequence analysis. With
the pre-diagnosis of hereditary hemochromatosis, c.100747G>A
heterozygous c.340+4 T>C heterozygous mutations were detected
in HFE gene mutation analysis (Fig. 2). Previously, c.100747G>A
mutation has been reported to be associated with iron overload
and c.340+4 T>C mutation is defined as the polymorphism associ-
ated with hemochromatosis [9].Fig. 1. (A and B) Heterozygous a thalassemia 3.7 deletion determined3. Discussion
For suspected hemochromatosis cases, ferritin level and fasting
transferrin saturation should be measured at first [10]. HFE gene
mutation analysis was performed in our case because of an
increase in ferritin levels in two-years period, and the patient
was diagnosed as hereditary hemochromatosis due to the detected
heterozygous mutations for 47G>A/+4T>C. According to our
knowledge, these mutations are reported in Turkish population
for the first time.
Ferritin increases in neoplasms and infections as an acute phase
reactant. Alcoholic liver disease, Hepatitis C infections, and non-
alcoholic steatohepatitis may also elevate ferritin levels [11].
Therefore, ferritin is not a specific marker for hemochromatosis
and transferrin saturation should be evaluated concurrently. In
case of normal levels of both ferritin and transferrin saturation,
hemochromatosis should be ruled out [12]. Transferrin saturation
levels above 45 are valuable for the diagnosis and HFE mutation
should be analysed. Prior to 1996 the diagnosis of hemochromato-
sis was made by liver biopsy. However, after the detection of HFE
gene mutations, genetic analysis substitute liver biopsy [13,14].
Our case was diagnosed as hereditary hemochromatosis based on
unaccompanied additional complaints, negative acute phase reac-
tants, increase in ferritin levels in two-years period, and detection
of HFE gene mutation.
Today, C282Y and H63D mutations are detected in whole blood
by polymerase chain reaction (PCR). Accumulation of iron in the
body and detection of homozygous C282Y mutation is sufficient
for the diagnosis of the disease [15]. C282Y homozygosity is the
most common mutation for hemochromatosis and proceeds with
maximum iron accumulation. While the patients with both
C282Y/H63D heterozygosity show moderate iron accumulation,
H63D homozygotes and C282Y heterozygotes are usually normal
[16]. These two mutations are previously defined in Turkish popu-
lation [7]. Genetic analysis may be useful for diagnosis of
hemochromatosis. However, only for patients with hepatic fibrosis
and cirrhosis liver biopsy is supportive [17].
Alpha-thalassemia is a hereditary anemia that results from a
defective synthesis of alpha-globin. Revise alpha-thalassemia can
be inherited or acquired and is originated by defects or deletions
in one or more genes of the four alpha-globin genes. Hypochromic
and microcytic cells characterize alpha-thalassemia [18].by MLPA method (SALSA MLPA P140 HBA probemix, MRC Holland).
Fig. 2. (A) Heterozigot c.100747G>A mutation, (B) Heterozigot c.340+4 T>C mutation.
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tion in the alpha-thalassemia for Caucasians was 13.70%. and for
the C282Y mutation the frequency observed 2.38% [19]. Besides,
Pietrangelo et al. found compound heterozygous patients (H63D/
C282Y) in the alpha-thalassemic patients [20].
In a study carried out in Hong Kong, iron overload in alpha-
thalassemia was not related to hemochromatosis mutations [21].
However, more data about the role of HFE mutations in alpha-
thalassemic patients are still necessary.
4. Conclusion
Although there are no complaints or symptoms, hemochro-
matosis can be detected incidentally by routine pediatric examina-
tion and blood analysis, and its diagnosis can be made easily by
mutation analysis.
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